BioNTech Sent Plummeting Following Damning Whistleblower Report, News of Covid-19 Pills

Shares of BioNTech (NASDAQ: BNTX) were sent into a nosedive on Friday, after a whistleblower report made scathing revelations surrounding trials of the Pfizer-BioNTech Covid-19 vaccine, of which the German company helped develop.

BioNTech plunged by as much as 20% on Friday to around $216 at the time of writing, after a whistleblower’s report revealed dramatic details into the trials of the Pfizer Covid-19 vaccine, which was co-developed alongside BioNTech and US company Pfizer. The report, which was published in the British Medical Journal earlier this week, cites revelations of former contractor Brook Jackson, whom allegedly exposes an alarming amount of incompetence in data handling and patient safety during the trial process.

Jackson claims that BioNTech allocated the task of conducting trials to poorly-trained vaccinators, whom failed to investigate adverse side-effects in a timely manner, and even went as far as to falsify certain data. The whistleblower submitted various internal documents to the journal to corroborate her claims.

Some analysts also attribute BioNTech’s dramatic decrease on the Nasdaq to the results of Pfizer’s Covid-19 pill. On Friday, the US company announced its trial data on Paxlovid, its “game-changer” pill, lessens hospitalizations from Covid-19 by 89%. Pfizer’s news also came just as another US pharma company, Merck & Co, revealed that clinical trials for its vaccine reduced the chances of hospitalization and death by 50% in patients with mild to moderate Covid-19 infection.

With the emergence of new Covid-19 drugs, investors have begun to anticipate that demand for vaccines would gradually decrease. Moderna, another major vaccine maker, also saw its stock plunge by more than $50 before paring back losses to around $236 at the time of writing.


Information for this briefing was found via Reuters. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

2026 Could Be Gold’s Biggest Year Yet!? | Ryan King – Equinox Gold

Gold Is Screaming Higher While Currencies Burn | Simon Ridgway – Rackla Metals

We Have the Highest-Grade Antimony Deposit in North America!? | Jim Atkinson -Antimony Resources

Recommended

Canadian Copper Secures $8 Million Lead Order From Ocean Partners As Part Of Larger Funding Round

Northern Superior Expands Philibert With 350 Metre Step Out Testing 1.10 g/t Gold Over 25.5 Metres

Related News

Pfizer Stock Unfazed By $9 Billion Cut In Revenue Projections

On the first day of trading following the Pfizer’s (NYSE: PFE) announcement of weaker-than-expected sales...

Monday, October 16, 2023, 03:51:00 PM

Former Pfizer Employee Charged by SEC for Insider Trading

Former Pfizer Inc. (NYSE: PFE) employee Amit Dagar and his close friend and business partner,...

Friday, June 30, 2023, 10:58:00 AM

BioNTech Sees Vaccine Sales Push Q1 Revenues To €6.4 Billion

While many may view the pandemic as being over, the financial results of BioNTech (NASDAQ:...

Monday, May 9, 2022, 08:02:20 AM

Pfizer To Acquire Clinical-Stage Biotech Firm Arena Therapeutics For US$6.7 Billion

Pfizer Inc. (NYSE: PFE) announced on Monday the definitive agreement to acquire clinical stage biopharmaceutical...

Friday, December 17, 2021, 10:58:00 AM

Well Health, Bombardier To Be Added To S&P/TSX Composite Index

The latest changes for the S&P/TSX Composite Index, assembled by S&P Down Jones Indices, were...

Sunday, September 5, 2021, 12:09:00 PM